FDA Approves Mydcombi (tropicamide and phenylephrine hydrochloride) Ophthalmic Spray forInducing Mydriasis
May 8, 2023FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause
May 12, 2023May 10, 2023 - Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx ® , have announced that the U.S. Food and Drug Administration (FDA) has approved Elfabrio (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.
Elfabrio is a PEGylated enzyme replacement therapy (ERT). It is a recombinant human α–Galactosidase–A enzyme expressed in plant-cell culture that is designed to provide a long half-life. The recommended dosage of Elfabrio, based on actual body weight, is 1 mg/kg administered by intravenous infusion every 2 weeks.